Jane Street
TVRD

Jane Street’s Tvardi Therapeutics TVRD Stock Holding History

Jane Street’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-522
Closed -$176K – 10325
2022
Q3 		$176K Buy
+522
New +$189K ﹤0.01% 8289
2022
Q2 		– Sell
-472
Closed -$207K – 11134
2022
Q1 		$207K Sell
472
-817
-63% -$335K ﹤0.01% 8990
2021
Q4 		$565K Sell
1,289
-928
-42% -$466K ﹤0.01% 7031
2021
Q3 		$1.23M Buy
2,217
+1,434
+183% +$719K ﹤0.01% 5494
2021
Q2 		$402K Sell
783
-1,192
-60% -$755K ﹤0.01% 7656
2021
Q1 		$1.54M Buy
1,975
+1,528
+342% +$1.05M ﹤0.01% 4529
2020
Q4 		$244K Buy
+447
New +$234K ﹤0.01% 6701
2020
Q3 		– Sell
-453
Closed -$279K – 8074
2020
Q2 		$279K Buy
+453
New +$250K ﹤0.01% 5944
2017
Q3 		– Sell
-1,042
Closed -$577K – 5195
2017
Q2 		$577K Buy
1,042
+339
+48% +$215K ﹤0.01% 2845
2017
Q1 		$465K Buy
+703
New +$376K ﹤0.01% 2965

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Jane Street's TVRD Position: Q1 2026 in Review

Jane Street sold out of Tvardi Therapeutics (TVRD) in Q1 2026, closing a stake of 47,444 shares — an estimated $204K sold.

Jane Street first reported a position in TVRD in Q1 2014 and held it in 25 quarters. The position peaked at $3.42M in Q3 2021. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • Jane Street reported no remaining Tvardi Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 47,444 Tvardi Therapeutics shares in Q1 2026, an estimated $204K.
  • Jane Street first reported a position in Tvardi Therapeutics in Q1 2014 and held it in 25 quarters.
  • Jane Street's Tvardi Therapeutics position peaked at $3.42M in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.